EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

JG Paez, PA Janne, JC Lee, S Tracy, H Greulich… - Science, 2004 - science.org
Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC)
and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene …

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non–small cell lung cancer

XL Mu, LY Li, XT Zhang, MZ Wang, RE Feng… - Clinical cancer …, 2005 - AACR
Purpose: Studies have shown that mutations in the epidermal growth factor receptor (EGFR)
tyrosine kinase domain are associated with response of lung cancer to gefitinib (Iressa …

Epidermal growth factor receptor mutations in patients with non–small cell lung cancer

BE Johnson, PA Jänne - Cancer research, 2005 - AACR
A year has passed since mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …

[HTML][HTML] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib

TJ Lynch, DW Bell, R Sordella… - … England Journal of …, 2004 - Mass Medical Soc
Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

W Pao, V Miller, M Zakowski… - Proceedings of the …, 2004 - National Acad Sciences
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor
(EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa) …

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

T Kosaka, Y Yatabe, H Endoh, K Yoshida, T Hida… - Clinical Cancer …, 2006 - AACR
Purpose: Non–small cell lung cancers carrying activating mutations in the gene for the
epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine …

Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification

T Okabe, I Okamoto, K Tamura, M Terashima… - Cancer research, 2007 - AACR
The identification of somatic mutations in the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) in patients with non–small cell lung cancer (NSCLC) and the …

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

H Ji, X Zhao, Y Yuza, T Shimamura… - Proceedings of the …, 2006 - National Acad Sciences
The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-
tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable …

EGFR exon 20 insertion mutation in Japanese lung cancer

H Sasaki, K Endo, M Takada, M Kawahara, N Kitahara… - Lung Cancer, 2007 - Elsevier
Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-
small cell lung cancer (NSCLC), especially in female, never smoker patients with …

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

K Taniguchi, J Okami, K Kodama… - Cancer …, 2008 - Wiley Online Library
Somatic mutations introduced into the epidermal growth factor receptor (EGFR) gene in non‐
small‐cell lung cancer (NSCLC) are important factors to determine therapeutic responses to …